论文部分内容阅读
从人体胎盘分离纯化ＧＳＴ－π并建立血清ＧＳＴ－π双抗夹心ＥＬＩＳＡ检测方法。检测了７３例正常人及１９３例消化道良、恶性肿瘤和非肿瘤患者血清ＧＳＴ－π含量。结果原发性肝癌、转移性肝癌、胃癌、结肠直肠癌和食道癌患者血清ＧＳＴ－π含量显著升高（Ｐ＜０．０１～０．０００１），阳性率分别为９０．６％、９０．０％、６８．４％、６６．６％和５７．０％，对消化道恶性肿瘤总的阳性率为７９．６％，特异性９５．４％。提示血清ＧＳＴ－π检测对消化道肿瘤的诊断具有较好的辅助诊断作用；特别是原发性肝癌，是一项较为敏感的肿瘤标志物。
GST-π was isolated and purified from human placenta and serum GST-π double antibody sandwich ELISA was established. The serum GST-π levels in 73 healthy subjects and 193 patients with benign and malignant digestive tract tumors and non-cancer patients were measured. Results The levels of serum GST-π in patients with primary liver cancer, metastatic liver cancer, gastric cancer, colorectal cancer and esophageal cancer were significantly increased (P<0.01 to 0.0001). The positive rates were 90.6% and 90.6%, respectively. 0%, 68.4%, 66.6%, and 57.0%. The total positive rate of malignant tumors in the digestive tract was 79.6% with a specificity of 95.4%. It is suggested that serum GST-π detection has a good auxiliary diagnostic role in the diagnosis of digestive tract tumors; in particular, primary liver cancer is a relatively sensitive tumor marker.